Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11027381 | 0.98 | HTR2A (0.38) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL27764905 | 0.83 | SLC6A4 (0.37) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL121630 | 0.82 | ALDH1A1 (0.41) | HTR2ASLC6A4HTR2CHTR2BP2RX7 | |
| SCHEMBL29569492 | 0.82 | ALDH1A1 (0.41) | HTR2ASLC6A4HTR2CHTR2BP2RX7 | |
| SCHEMBL14774701 | 0.80 | SGMS2 (0.43) | HTR2ASLC6A4KCNH2HTR2CSLC6A2 | |
| SCHEMBL2370502 | 0.79 | SLC6A4 (0.40) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL3307736 | 0.78 | IDO1 (0.40) | HTR2ASLC6A4PSEN1PSEN2APH1B | |
| SCHEMBL30149750 | 0.78 | IDO1 (0.40) | HTR2ASLC6A4PSEN1PSEN2APH1B | |
| SCHEMBL149727 | 0.77 | SLC6A4 (0.39) | HTR2ASLC6A4KCNH2PSEN1PSEN2 | |
| SCHEMBL919255 | 0.77 | PNMT (0.48) | HTR2ASLC6A4KCNH2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055361-A | Fascin inhibitors | 北京双鹤润创科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4720054-A1 | FASCIN INHIBITORS | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250090540-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2024240245-A1 | FASCIN INHIBITORS | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2024-11-28 | — | — | WO | disclosed |
| EP-4399196-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092895-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| US-6034092-A | ANTITUMOR, ANTICANCER AGENTS | NOVUSPHARMA S.P.A. (IT) | 2000-03-07 | — | — | US | disclosed |
| EP-0876369-A1 | 2- 2- (2-HYDROXYETHYL)AMINO]ETHYL]-5- 2-METHYLAMINO)ETHYL]AMINO]INDAZOLO 4,3-gh]ISOQUINOLIN-6(2H)-ONE AS ANTITUMOR AGENT | BOEHRINGER MANNHEIM ITALIA S.p.A. (IT) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997010245-A1 | 2-[2-[(2-HYDROXYETHYL)AMINO]ETHYL]-5-[[2-METHYLAMINO)ETHYL]AMINO]INDAZOLO[4,3-gh]ISOQUINOLIN-6(2H)-ONE AS ANTITUMOR AGENT | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1997-03-20 | — | — | WO | disclosed |
| US-4405357-A | Herbicidal 3-isoxazolidinones and hydroxamic acids | FMC CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | HTR2A 2662/4885SLC6A4 4134/4885KCNH2 330/4885 |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | HTR2A 240/4885SLC6A4 254/4885KCNH2 2353/4885 |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | HTR2A 2173/4885SLC6A4 4147/4885KCNH2 1690/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | HTR2A 4250/4885SLC6A4 4836/4885KCNH2 4722/4885 |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | HTR2A 3461/4885SLC6A4 283/4885KCNH2 2894/4885 |
| US-20250090540-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | HTR2A 3716/4885SLC6A4 4629/4885KCNH2 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.